Group One Trading
BCRX icon

Group One Trading’s BioCryst Pharmaceuticals BCRX Stock Holding History

Group One Trading’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$598K Buy
62,800
+1,700
+3% +$13.2K ﹤0.01% 3179
2025
Q4 		$477K Buy
61,100
+6,200
+11% +$44.8K ﹤0.01% 3566
2025
Q3 		$417K Sell
54,900
-12,300
-18% -$102K ﹤0.01% 3880
2025
Q2 		$602K Sell
67,200
-900
-1% -$8.38K ﹤0.01% 3227
2025
Q1 		$511K Buy
68,100
+14,300
+27% +$115K ﹤0.01% 3064
2024
Q4 		$405K Buy
53,800
+9,800
+22% +$74.4K ﹤0.01% 3354
2024
Q3 		$334K Sell
44,000
-15,600
-26% -$119K ﹤0.01% 3167
2024
Q2 		$368K Buy
59,600
+13,600
+30% +$75K ﹤0.01% 2847
2024
Q1 		$234K Sell
46,000
-79,800
-63% -$449K ﹤0.01% 3428
2023
Q4 		$754K Sell
125,800
-39,700
-24% -$230K ﹤0.01% 2722
2023
Q3 		$1.17M Buy
165,500
+14,400
+10% +$103K ﹤0.01% 2103
2023
Q2 		$1.06M Sell
151,100
-4,600
-3% -$36.9K ﹤0.01% 2309
2023
Q1 		$1.3M Sell
155,700
-286,400
-65% -$2.76M ﹤0.01% 1911
2022
Q4 		$5.08M Buy
442,100
+198,700
+82% +$2.48M 0.01% 1137
2022
Q3 		$3.07M Sell
243,400
-70,400
-22% -$906K 0.01% 1558
2022
Q2 		$3.32M Buy
313,800
+115,600
+58% +$1.19M 0.01% 1607
2022
Q1 		$3.22M Sell
198,200
-172,100
-46% -$2.76M ﹤0.01% 1917
2021
Q4 		$5.13M Sell
370,300
-119,300
-24% -$1.58M ﹤0.01% 1679
2021
Q3 		$7.04M Buy
489,600
+149,200
+44% +$2.35M 0.01% 1380
2021
Q2 		$5.38M Sell
340,400
-19,700
-5% -$268K 0.01% 1616
2021
Q1 		$3.66M Buy
360,100
+27,600
+8% +$285K 0.01% 1838
2020
Q4 		$2.48M Buy
332,500
+214,400
+182% +$1.11M ﹤0.01% 1876
2020
Q3 		$406K Buy
118,100
+80,000
+210% +$343K ﹤0.01% 3029
2020
Q2 		$182K Buy
38,100
+21,600
+131% +$86.3K ﹤0.01% 3454
2020
Q1 		$33K Buy
16,500
+5,600
+51% +$15.4K ﹤0.01% 3966
2019
Q4 		$38K Sell
10,900
-12,200
-53% -$30.7K ﹤0.01% 4125
2019
Q3 		$66K Sell
23,100
-182,300
-89% -$567K ﹤0.01% 3833
2019
Q2 		$778K Buy
205,400
+201,900
+5,769% +$1.21M 0.01% 1768
2019
Q1 		$28K Buy
3,500
+500
+17% +$4.28K ﹤0.01% 3875
2018
Q4 		$24K Sell
3,000
-2,000
-40% -$15.6K ﹤0.01% 3941
2018
Q3 		$38K Sell
5,000
-7,500
-60% -$50.4K ﹤0.01% 4118
2018
Q2 		$72K Buy
12,500
+6,800
+119% +$37.4K ﹤0.01% 3744
2018
Q1 		$27K Sell
5,700
-33,600
-85% -$173K ﹤0.01% 3960
2017
Q4 		$193K Sell
39,300
-164,200
-81% -$795K ﹤0.01% 2946
2017
Q3 		$1.07M Buy
203,500
+139,400
+217% +$714K 0.01% 1517
2017
Q2 		$356K Buy
64,100
+14,200
+28% +$86.5K ﹤0.01% 2209
2017
Q1 		$419K Sell
49,900
-1,400
-3% -$9.74K ﹤0.01% 1965
2016
Q4 		$325K Sell
51,300
-5,200
-9% -$27.1K ﹤0.01% 2067
2016
Q3 		$249K Buy
+56,500
New +$226K ﹤0.01% 2312
2016
Q1 		– Sell
-20,400
Closed -$211K – 4556
2015
Q4 		$211K Sell
20,400
-200
-1% -$1.99K ﹤0.01% 2455
2015
Q3 		$235K Sell
20,600
-52,600
-72% -$702K ﹤0.01% 2389
2015
Q2 		$1.09M Buy
73,200
+55,500
+314% +$631K 0.02% 1148
2015
Q1 		$160K Sell
17,700
-13,100
-43% -$136K ﹤0.01% 2549
2014
Q4 		$375K Buy
30,800
+16,800
+120% +$186K 0.01% 1783
2014
Q3 		$137K Sell
14,000
-19,700
-58% -$241K ﹤0.01% 2718
2014
Q2 		$430K Buy
33,700
+2,000
+6% +$19.5K 0.01% 1764
2014
Q1 		$335K Buy
31,700
+10,300
+48% +$110K 0.01% 1992
2013
Q4 		$163K Sell
21,400
-117,100
-85% -$742K ﹤0.01% 2614
2013
Q3 		$1.01M Buy
138,500
+122,700
+777% +$622K 0.02% 1013
2013
Q2 		$24K Buy
+15,800
New +$27.3K ﹤0.01% 3963

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Group One Trading's BCRX Position: Q1 2026 in Review

Group One Trading increased its BioCryst Pharmaceuticals (BCRX) stake by 125% in Q1 2026, buying an estimated $588K and bringing the position to 136,282 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2468.

Group One Trading first reported a position in BCRX in Q2 2013 and has held it in 37 quarters since. The position peaked at $1.92M in Q4 2021. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Group One Trading held 136,282 shares of BioCryst Pharmaceuticals worth $1.3M as of Q1 2026.
  • Group One Trading bought 75,758 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $588K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #2468 holding.
  • Group One Trading first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 37 quarters since.
  • Group One Trading's BioCryst Pharmaceuticals position peaked at $1.92M in Q4 2021.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.